1145 ET - H. Lundbeck's $2.6 billion deal to buy Longboard Pharmaceuticals underscores the industry's growing in interest in developmental and epileptic encephalopathies, or DEEs, and rare epilepsies, analysts at Truist say. In a research note, Truist says the Longboard deal, which carries a 54% premium, has positive derivative read-throughs to the likes of Praxis Precision Medicines, Marinus Pharmaceuticals and Jazz Pharmaceuticals, all of which have drugs approved or in development for DEE. Praxis up 6.3, Marinus up 2.3% and Jazz up 1.1%. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
October 14, 2024 11:45 ET (15:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。